Department of Emergency Medicine, Ordu University Faculty of Medicine, Ordu, Turkey.
Department of Parasitology, Ordu University Faculty of Medicine, Ordu, Turkey.
Trop Biomed. 2021 Sep 1;38(3):366-370. doi: 10.47665/tb.38.3.080.
Many biomarkers are used in addition to radiologic examinations to determine the severity of COVID-19. This study aims to determine WBC, neutrophil, lymphocyte, platelet, D-dimer, CRP, AST, ALT, LDH, PT, APTT, INR, urea, creatinine, lactate, and ferritin levels in COVID-19 patients and the effect of their changes on mortality rate. The study was conducted between 11 March 2020 and 31 August 2020 (during the COVID-19 pandemic). A total of 502 patients older than 18 years who presented with suspected COVID-19 were included in the study. Of these 502 patients who applied to the hospital, 229(45.6%) were male and 273(54%) were female. 301(60%) patients were diagnosed with COVID-19 through computed tomography and PCR tests. 201(40%) patients with negative test results constituted the control group. Patients with positive test results 48.2% (n=145) were men, and 51.8% (n=156) were women. The median age of the patients was 51±25 years. The patients tested positive for COVID-19 were divided into three groups as outpatients (26.9%), inpatients (68.8%), and intensive care unit patients (4.3%). The mortality rate of the patients followed via the patient follow-up system after 30 days was determined as 2.7%. The biomarker values of patients examined in this study tested negative and positive for COVID-19 were compared. In the study, D-dimer, ferritin, Lactate, AST, ALT, LDH, Urea, Creatinine, APTT, and INR levels were found to be higher in the positive tested patients than the negative ones. In the study, it was concluded that neutrophil, lymphocyte, CRP, and ferritin ratios should also be followed in the follow-up phase of the disease. It is important that additional measures should be taken in cases when these biomarkers increase by following the values of the patients who started taking treatment. Also, the ratio of biomarkers is crucial in determining whether the treatment has been effective or not.
除了影像学检查外，还有许多生物标志物用于确定 COVID-19 的严重程度。本研究旨在确定 COVID-19 患者的白细胞计数（WBC）、中性粒细胞、淋巴细胞、血小板、D-二聚体、C 反应蛋白（CRP）、天门冬氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）、乳酸脱氢酶（LDH）、凝血酶原时间（PT）、部分凝血活酶时间（APTT）、国际标准化比值（INR）、尿素、肌酐、乳酸、铁蛋白水平，并研究其变化对死亡率的影响。本研究于 2020 年 3 月 11 日至 2020 年 8 月 31 日（COVID-19 大流行期间）进行。共纳入 502 例年龄大于 18 岁、疑似 COVID-19 的患者。502 例患者中，229 例（45.6%）为男性，273 例（54%）为女性。301 例（60%）患者通过计算机断层扫描和 PCR 检测确诊为 COVID-19。201 例（40%）检测结果为阴性的患者为对照组。阳性组患者中，48.2%（n=145）为男性，51.8%（n=156）为女性。患者的中位年龄为 51±25 岁。COVID-19 检测阳性的患者分为门诊（26.9%）、住院（68.8%）和重症监护病房（4.3%）三组。通过患者随访系统随访 30 天后，患者的死亡率为 2.7%。比较了本研究中检查的 COVID-19 阴性和阳性患者的生物标志物值。研究发现，与阴性组相比，D-二聚体、铁蛋白、乳酸、AST、ALT、LDH、尿素、肌酐、APTT 和 INR 水平在阳性组患者中更高。在研究中还得出结论，在疾病的随访阶段，还应监测中性粒细胞、淋巴细胞、CRP 和铁蛋白比值。在开始治疗的患者中，当这些生物标志物增加时，应根据其值采取额外的措施，这一点很重要。此外，生物标志物比值在确定治疗是否有效方面也很重要。
